Ipamorelin Research: What Published Studies Have Investigated

What is Ipamorelin?

What is Ipamorelin? It is a synthetic pentapeptide of five amino acids, with the sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2. It was first described by Raun et al. (European Journal of Endocrinology, 1998) as “the first selective growth hormone secretagogue.” In pharmacological terms it acts as an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a) — the same receptor bound by the endogenous hormone ghrelin — and for that reason it is also described as a ghrelin-receptor agonist or ghrelin mimetic. That is a neutral molecular definition; the sections below describe what researchers examined, not effects in people.

The phrase “selective growth hormone secretagogue” is a term of art from that 1998 report and is used throughout this page in its narrow, literature-defined sense: it describes how the molecule behaves at the receptor in study systems, and nothing on this page should be read as a statement of what it does in a person. It is worth stating at the outset that the great majority of the published record is preclinical — cell assays and rodent models — and that the single small human interventional study addressed a gastrointestinal-motility question, not a body-composition one.

Molecule properties

Ipamorelin is a pentapeptide of five residues, carrying a C-terminal amide (amidation) and several non-natural residues — Aib (2-aminoisobutyric acid), D-2-Nal, and D-Phe — that distinguish it from earlier peptidyl secretagogues built from standard L-amino acids. Those non-natural residues are a molecule-history detail rather than a functional promise. In research catalogues it is supplied as a lyophilized powder and is handled as a synthetic research peptide, which is why it is worth drawing the distinction between the endogenous ligand at this receptor (ghrelin, a 28-amino-acid hormone) and this much smaller synthetic peptide studied in the laboratory. Molecule facts only — no handling or reconstitution instructions.

Mechanisms researchers have examined

The Ipamorelin mechanism literature centres on the ghrelin/GHS-R1a receptor pathway. Each direction below is framed as what researchers examined, not as an effect in a reader:

• Selective GH-secretagogue activity via GHS-R1a — Raun et al. (1998) reported that Ipamorelin releases growth hormone in vitro and in vivo through the ghrelin/GHS receptor pathway, with activity described at the pituitary and hypothalamic level. This is the receptor pharmacology the paper set out to characterize.
• Selectivity (minimal ACTH / cortisol / prolactin release) — the same study characterized Ipamorelin as releasing GH without stimulating ACTH or cortisol at levels significantly above GHRH-stimulated controls, a selectivity that distinguished it in that work from earlier secretagogues such as GHRP-6. This is reported here strictly as a neutral characterization of receptor selectivity — not as a benefit, an advantage, or a reason to prefer the compound.
• Distinct from the GHRH-analog mechanism — Ipamorelin is a ghrelin-receptor agonist, a mechanism separate from GHRH analogs such as CJC-1295, which act at the GHRH receptor. The two are studied at different receptors; this is a mechanism contrast only, and nothing here suggests combining them.
• Peripheral ghrelin-receptor / GI-motility signalling — Venkova et al. (2009, J Pharmacol Exp Ther) examined Ipamorelin as a ghrelin mimetic acting on gut GHS receptors in a rodent gastrointestinal-motility model.

A recurring point in the reviews of this class, such as Ishida et al. (2020), is that the ghrelin/GHS-R1a axis was mapped largely through synthetic secretagogues of this kind, and that the receptor is expressed both centrally (pituitary and hypothalamus) and peripherally (including the gut) — which is why the same receptor label appears in both the GH-release work and the gastrointestinal-motility work above. The section closes as the literature does: Ipamorelin is characterized as a selective ghrelin-receptor agonist, and these mechanisms are described primarily in cell and animal models. Each bullet names a pathway examined, not an outcome in a reader.

Research models in the literature

Preclinical work dominates. On the in-vitro and rodent side, Raun et al. (1998) used pituitary/cell assays and rodent models of GH release to characterize the receptor pharmacology, while Venkova et al. (2009) examined Ipamorelin as a ghrelin mimetic in a rodent model of postoperative ileus — a gastrointestinal-dysmotility model rather than a body-composition one. These are animal and cell studies, and findings in such models cannot establish outcomes in people.

On the human side, described neutrally, the interventional record is very limited. A single small phase-2, randomized, double-blind, placebo-controlled proof-of-concept trial examined Ipamorelin for postoperative ileus in bowel-resection patients (Beck et al., 2014, International Journal of Colorectal Disease). Reported accurately: the compound was tolerated in that trial, but the study’s primary efficacy endpoint was not met. That is stated plainly here — neither spun as a success nor dismissed as a failure beyond what the paper reports. The honest summary is worth repeating: the human interventional literature is very limited and sits in a gastrointestinal-motility indication, not body composition, and the broader evidence base is preclinical. That framing matters because the vendor pages this explainer is written against routinely present body-composition outcomes that the published human record does not support.

Ipamorelin among the growth-hormone secretagogues

In research-focus terms, Ipamorelin is grouped with the growth-hormone secretagogues and is usually positioned by its receptor target. The class splits along two receptors: the ghrelin receptor (GHS-R1a), where Ipamorelin and the GHRP family act, and the GHRH receptor, where GHRH analogs such as CJC-1295 and tesamorelin act. What distinguishes Ipamorelin as a research target within its own arm is the reported selectivity described above — again, a neutral receptor-pharmacology characterization, not a ranking or a recommendation. This is family and receptor context only; it is not stacking or use advice, and the review by Ishida et al. (2020) is a useful map of where the selective secretagogues sit within the wider GHS class. Because the two receptor families are so often blurred together on vendor pages, the distinction is worth stating once more in plain terms: a ghrelin-receptor agonist and a GHRH analog are different molecules acting on different receptors, and the published mechanism work treats them as separate questions rather than as parts of a single regimen.

Research-grade sourcing and verification

For laboratory research use only, Ipamorelin is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation at the lot level. Check the exact batch on the self-serve verify tool, and see how to read a COA for what the certificate reports. Sourcing and identity-assurance framing only — nothing here speaks to outcomes.

Frequently asked questions

Literature cited

1. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. “Ipamorelin, the first selective growth hormone secretagogue.” European Journal of Endocrinology. 1998;139(5):552–561. PMID 9849822.
2. Venkova K, Mann W, Nelson R, Greenwood-Van Meerveld B. “Efficacy of ipamorelin, a novel ghrelin mimetic, in a rodent model of postoperative ileus.” Journal of Pharmacology and Experimental Therapeutics. 2009. PMID 19289567.
3. Beck DE, Sweeney WB, McCarter MD. “Prospective, randomized, controlled, proof-of-concept study of the ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients.” International Journal of Colorectal Disease. 2014;29(12):1527–1534. PMID 25331030.
4. Ishida J, et al. “Growth hormone secretagogues: history, mechanism of action, and clinical development.” JCSM Rapid Communications. 2020;3(1):25–37.